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1. Introduction
Poisoning is one of the leading causes of mortality and morbidity in many countries. In 1955,
poisoning was the most common cause of death in patients aged between 35 and 44 years [1].
Tramadol was first manufactured in Germany in 1970 to relieve post-surgical and chronic pains
[2]. It is currently the most commonly prescribed opioid in the world [3]. According to the
Australian studies, tramadol use has increased almost 10 times between 1998 and 2004 [4].
Although tramadol is very commonly prescribed, it should be administered with the consid‐
eration of the risk to benefit ratio [5]. Tramadol is one of the most common causes of poisoning
in adult male patients with the previous history of drug addiction and psychological problems
and suicide is the most common motivation for its use in this group of the patients [1,3,6-8].
The aim of this review is to evaluate all possible clinical manifestations and life-threatening
signs/symptoms of tramadol poisoning.
2. Pharmacology
Tramadol is a synthetic analogue of codeine with central effects [2,6,9-13]. It is not an opioid
derivative or non steroidal anti-inflammatory (NSAID) medication. Actually, tramadol has
low affinity for opioid receptors [14,15] and has a hydrochloride structure (Figure 1) [1,16].
Tramadol is used as a racemic mixture in the treatments [15]. This mixture is a 1:1 ratio of two
enantiomers with synergistic analgesic effects [17]. The (+) and (-) enantiomers weakly connect
to mu opioid receptors [18]. Enantiomer (+) is the opioid part but increases serotonin release
and inhibits its re-uptake, as well. Enantiomer (-) is a noradrenaline re-uptake inhibitor [17-19].
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Most of the analgesic effects of tramadol are likely secondary to its monoaminergic central
pathways [3,10,20]. Tramadol acts through some different pathways including:
a. Affecting mu receptors causing the opioid-like effects;
b. Affecting noradrenergic pathways causing inhibition of norepinephrine reuptake in
central nervous system (CNS);
c. Affecting serotonergic pathways causing inhibition of serotonin reuptake in the CNS;
d. Affecting GABAergic pathways causing increased GABA neurotransmitter in the brain
[2,8,13,17,21,22].
Tramadol is currently available as tablets, oral drops, solution for injection, and suppository
[8] with the oral rout being the most common rout of its administration. Tramadol has a high
volume of distribution (3 L/kg) [3,7]. Bioavailability of an oral dose of tramadol is 75% which
can reach almost 100% with a programmed schedule [7]. The common therapeutic dose of
tramadol is 50 to 100 mg (50 mg oral, 50-100 mg intramuscular [IM], and/or100 mg rectal; 1.5
mg/kg/day in a 60-kg patient) three to four times a day. Doses higher than 400 mg/day are
generally not necessary [8,17,23]. However, evaluation of five rheumatologic disorder patients
over 65 years of age revealed that a daily tramadol dose of 300 to 1200 mg was needed for them
to relieve their pain [24].
Analgesic effects of tramadol are dose-related. The relation between serum level and analgesic
effect is not the same among different people. It is estimated that the normal therapeutic serum
level of tramadol and its metabolite are 0.1 to 0.3 mg/L and 0.03 to 0.04 mg/L, respectively
[3,25-27]. According to the information from International Association of Forensic Toxicolo‐
gists, therapeutic, toxic, and fatal levels of tramadol in adults are 0.1-0.8 mg/L, 1-2 mg/L, and
over 2 mg/L, respectively [26]. Tramadol is completely and rapidly absorbed after oral use.
Sustained-release tablets affect within 12 hours and their serum level peaks at 4-9 hours
postingestion [6]. In the mice, tramadol is more available and effective at the final phase of the
darkness and most of the mortalities happen at the mid phase of the darkness; such an effect
has not been detected in human volunteers [28,29].
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Figure 1. Tramadol structure
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In postmortem evaluations using gas chromatography, tramadol level is at the most in heart,
liver, peripheral blood, urine, kidney, lung, spleen, bile, and brain without any distribution
into the muscles [6,25,30].
Tramadol is generally metabolized through N-demethylation, O-demethylation, glucuroni‐
dation, and/or sulfation. Metabolization of tramadol is performed by cytochrome P450
enzymes. CYP2D6 is responsible for O-demethylation while N-demethylation is done by
CY2B6 and CY3A4 [6,31,32]. Tramadol can be used in renal failure although decreased doses
are recommended in renal problems and liver cirrhosis [33].
In a study on six alpacas (some kind of camel), the half-life of all three metabolites of tramadol
(O-, N-, and Di-desmethyltramadol) was reported to be more than the parent drug [34]. The
main metabolite (O-desmethyltramadol) has a 200-time affinity for mu receptors and its
analgesic effect is twice the parent medication, as well [2,15,26].
3. Tramadol toxicity
Tramadol is considered to be a safe drug. However, mortality has been reported with its use
[35,36]. Toxicity can happen accidentally. Patients with the previous history of addiction are
at extreme danger for such toxicity and according to FDA warnings, tramadol administration
should be performed cautiously in these patients [6,37].
Toxicity of tramadol can be predicted by P450 polymorphism [38,39]. Few studies have shown
the difference in the postsurgical analgesic serum levels of tramadol among people which is
probably due to the genetic polymorphism in the activity of CYP2D6 [40,41]. Diversity in the
response depends on the CYP2D6 genotype. Ultra-rapid metabolizers have a higher risk of
tramadol toxicity with higher plasma levels of O-desmethyltramadol. They experience higher
analgesic effects and nausea in comparison to the group who are extensive metabolizers [38].
4. Epidemiology of tramadol toxicity
Most of the tramadol-intoxicated patients are male (63% to 89.3%) [3,21,37,42-48] and single
[1,8,21]. However, in few studies, female patients were more (55% to 59%) [49,50]. Most of the
patients were in their 3rd decade of life. This is while the age range of the patients was reported
to be between 5-week-old and 87-year-old in different studies [1,3,8,37,44,45,47-51]. Patients
generally ingested tramadol [6,8,45,52]. Almost 51.9% to 98.7% of the patients had intentionally
overdosed on tramadol; 27.8% to 29.6%, 0.87% to 3.7%, and 0.2% to 7.4% had recreationally,
accidentally, or medically overdosed on tramadol, respectively [1,3,6,8,23,45].
In a recent study, university students with the previous history of cigarette smoking and
consumption of addicting opioids were more prone to abuse tramadol [24]. In another study,
22.2% of the hospitalized patients had a history of admission due to tramadol overdose [3]. It
has been said that in almost 90%, 7.9%, and 2.1% of the tramadol toxicities, poisoning is due
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to acute, chronic, and acute on chronic overdoses [3]. Most of the patients refer within the first
6 hours postingestion [21,45,49] with a hospitalization period of 15 minutes to 21 days [8,21].
Signs/symptoms of toxicity recover within 24 hours and almost 42% of the patients will need
ICU admission [49,50,53].
5. Biologic characteristics
Tramadol is used as the first-line treatment in musculoskeletal pains [15,54-57] and as an
alternative treatment in osteoarthritis (OA) patients in whom NSAIDs are contraindicated or
those with resistant pain to oral analgesics [58].
Tramadol analgesic effects are due to the inhibition of norepinephrine and serotonin reuptake
as well as agonism of mu receptors which cause blockage of the pain impulses in the spinal
cord [7,56,59]. Direct administration of tramadol on the sciatic nerve can reduce the amplitude
and speed of spinal somatosensory evoked potential in the rats emphasizing the analgesic
effects of tramadol on the peripheral nerves [60].
In tramadol-induced anesthesia, the patient become conscious rapidly, has amnesia during
the surgery, and experiences few side effects [61]. Controlled release of tramadol through
polyhydroxybutyrate (PHB) microspheres is also available which induces longer anesthesia
after epidural use in comparison with tramadol alone [62].
According to a study performed on the rats, tramadol reinforces the immune system by
increasing phagocytosis. Use of tramadol is therefore favored as an analgesic in immune-
compromised patients [63].
6. Side effects and clinical/paraclinical findings
Tramadol is an analgesic with less side effects in comparison with other opioids [64]. It has the
least gastrointestinal and renal toxicities [65]. Drug screening for opioids is generally negative
in the patients with tramadol overdose [66].
In overdose, lethargy, nausea, tachycardia, agitation, seizure, coma, hypotension, hyperten‐
sion, respiratory depression, dysuria, constipation, dizziness, facial paresthesia, ataxia,
headache, edema, movement disorders, perspiration, blurred vision, hallucination, itching,
vertigo, palpitation, hypo- and hyper-reflexia, diplopia, multi-organ failure, acute liver failure
due to fulminant liver necrosis, renal failure, and urine retention have been reported [8,17,23,
48-51,64,67,68]. Dizziness, nausea, constipation, vertigo, and headache are the most common
symptoms [57,69,70]. Miosis is not as common as that in toxicities with other opioids and is
detected in up to one-thirds of the patients probably due to serotonin and norepinephrine
reuptake inhibition [71].
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7. CNS manifestations of tramadol toxicity
The CNS manifestations are of the most common signs/symptoms of tramadol overdose
ranging from CNS depression to lethargy and deep coma [6]. O-desmethyltramadol impairs
consciousness and causes electrocardiographic (ECG) changes and seizure [44]. n a study by
Spiller et al, significant neurologic toxicity was seen in tramadol overdose [49] which was
mainly due to the monoamines reuptake inhibition [3,72].
In sub-acute and chronic toxicities, clinical manifestations are mostly behavioral disorders and
seizure and may occur with doses of 25mg/kg or higher [17]. Seizure is an important problem
in tramadol toxicity with its frequency being reported between 8% and 14% in different social
studies and 15% to 55.3% in hospital studies. Most of the patients experience only one episode
of seizure [44,47, 49,50]. Seizure is more common in young males (mean age of 22 – 39.5 y)
[8,23,43,44,52]; however, some studies reported no significant difference in the frequency of
seizure between different genders [3,47,72,73].
Seizure happens in less than 1% of the patients with therapeutic levels [23,74]. It seems that
tramadol causes seizure in a dose-dependent manner [3,21,23] while some other studies have
not confirmed this [43,44,75]. The least tramadol amount that has resulted in seizure is 100 mg.
Tramadol neurotoxicity generally occurs within the first 24 hours postingestion (mainly in the
first 6 hours) and seizures are usually tonic-clinic [3,6-8,11,21,23,50,75-78]. Status epilepticus
has also been reported [6,11,59,76]. This shows that tramadol can cause seizure at both
therapeutic and toxic levels [43,52,77,79].
Brain computed tomography (CT) of the tramadol-intoxicated patients has often been reported
to be normal [43,77]. Künig and assistants reported two cases of fluctuating dizziness and
cognitive problems due to long-term treatment with tramadol who recovered with cessation
of the drug [80]. In a study performed to evaluate the risk of idiopathic seizure in tramadol
users, only 17 cases of idiopathic seizure were found among 10917 patients, all of whom, used
tramadol in combination with some other medication; it, therefore, is difficult to relate their
seizure to tramadol use [71]. Seizure is less frequent in the patients who use tramadol with
benzodiazepines. Psychological and somatic complications (hepatitis C and liver injury) were
detected in those who had seized. Ethanol can reduce the seizure threshold in tramadol use.
Seizure is also more common in younger patients who have abused tramadol for a long period
of time [23].
Background seizing disorders, medications causing seizure, ethanol withdrawal, CNS
depressants, or head injury can affect seizure occurrence in tramadol overdose, as well [45].
Mydriasis and tachycardia can accompany with a higher risk of seizure [44].
In a cohort study comparing 9218 tramadol users and 37232 non-users, less than 1% of the
users experienced seizure after the first use. Risk of seizure was 2-to 6-fold in the patients who
had background diseases or consumed other medications. The risk was also higher in those
between 25 and 54 years of age, those who use tramadol for more than 4 times, or those with
the history of alcohol abuse, infarction, or head injury [74].
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In another study on 97 patients with seizure,  electroencephalographic (EEG) evaluations
were normal in seven and isolated sharp slow-wave feature of EEG was seen in one patients.
Brain CT was normal in all  and magnetic  resonance imaging (MRI)  was normal in five
patients [77]. Tramadol-induced seizure can cause trauma, intra-articular dislocation, and
tongue laceration [67,81,82].
In a study on 70 rats, it was revealed that tramadol could inhibit electron transfer cycle (ETC),
cause ATP depletion, and disrupt the mitochondrial integrity. Apoptosis may also happen due
to tramadol use [83]. In the neonates, tramadol can trigger pentylenetetrazole-induced seizure
in an age-dependant manner causing fewer seizures in the neonatal period and more seizures
after the lactating period [84].
Administration  of  tramadol  hydrochloride  to  a  zebrafish  caused  abnormal  behaviors,
reduced activity,  and reduced brain and body weight.  In the zebrafish brain,  functional
cytoskeletal  proteins  engaged  in  the  energy  metabolism  had  changed  due  to  tramadol.
Lower  levels  of  ATP  synthetase,  creatine  kinase,  pyruvate  dehydrogenase,  kinase,  and
aldolase C could be due to the impaired production of energy because of tramadol. Weak
regulation  of  the  proteins  engaged  in  the  oxidative  stress,  mitochondrial  functional
abnormalities,  and impaired production and destruction of  the  proteins  represented the
neurotoxicity of tramadol (Table 1) [85].
Authors Publication
year
Number of
patients
Cause of
ingestion
Sex Co-
administration
or comorbidity
Dosage
Raigeret al.
[139]
2012 1 Prescribed
by physician
Female History of
seizure
100 mg IV
Petramfar et al.[140] 2010 106 Prescribed
by physician
in 18.9%
Abuse in
81.1%
96% M History of
epilepsy in
13.2%, abuse of
antidepressant in
5.8%, alcohol in
5.8%, opiate in
23.3%
50-1500 mg IV or
oral
Mehrpour M
[141]
2005 2 Prescribed
by physician
F/M _ 100 mg IV
Table 1. Studies on tramadol-induced seizures
8. Cardiopulmonary effects of tramadol
Acute pulmonary hypertension and right heart failure are the uncommon presentations
reported in a young tramadol-overdosed patient [86]. Cardiopulmonary arrest was reported
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in some cases that had ingested more than 5 g of tramadol [8]. Higher doses of tramadol can
block sodium channels and cause Brugada pattern in the ECG [11,47] which can be accompa‐
nied by ventricular dysrhythmias including ventricular fibrillation [11]. In a study on 479
tramadol-poisoned patients, up to 73% of the patients had ECG changes due to blockage of
the sodium channels. Almost one-thirds of the patients had terminal 40 msec frontal plane axis
deviation and one-fourth had QT prolongation (more than 0.44 sec) [47]. Some cases of right
heart failure, resistant shock, asystole, hypotension (especially systolic), and sinus tachycardia
have also been recorded [6,35,44,49]. Hypertension has also been reported. The least tramadol
dose that has resulted in hypertension and agitation is 500 mg [49].
Eleven suspected cases of tramadol-related angioedema have been reported from Sweden.
Involvement of the mouth/pharynx and upper respiratory system can progress to acute
respiratory distress and airway obstruction [87]. Tramadol causes respiratory depression with
less frequency in comparison with other opioids [28,57,88]. Renal failure is a probable risk
factor for respiratory depression [28,89]. Tramadol overdose can cause respiratory depression;
but in therapeutic oral doses, it does not cause respiratory complications. In a study on IV
administration of 50 to 75 mg of tramadol, no significant changes were detected in the
respiratory rate, respiratory volume per minute, and arterial PaO2 [90].
9. Hepatic system
Sixteen cases of non-fatal hepatobiliary dysfunction due to tramadol ingestion have been
reported [74]. Tramadol has caused centrilobular congestion and focal necrosis of the liver cells
and minimal vacuolization in the kidney tubular cells of the rats. No changes were detected
in the lactate dehydrogenase, blood urea nitrogen (BUN), aspartate aminotransferase (AST),
and malondialdehyde (MDA); however, alanine aminotransferase (ALT) increased signifi‐
cantly showing the possible hepatotoxicity of tramadol [91]. It was shown that acute or chronic
toxicity did not affect liver weight or cause histopathological changes in its tissue [17,92].
In the rats, mu receptor activation increases glucose use or decreases the liver gluconeogenesis
which results in the low levels of plasma glucose in diabetic rats [88,93]. It has been shown
that tramadol improves the peripheral metabolism of glucose by central activation of the mu
receptors. Therefore, central and peripheral metabolisms of glucose unite and cause hypogly‐
cemia. It has also been suggested that tramadol changes the liver glucose output regulated by
other organs (likely CNS) [93].
10. Gastrointestinal system
Although tramadol is fairly tolerated after ingestion, nausea and vomiting may happen in 14%
to 75 % of the cases after its oral use [8,49]. Some patients discontinue tramadol consumption
because of nausea and vomiting. It has been shown that slow titration decreases the frequency
of tramadol discontinuation due to these complications [94].
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11. Carcinogenic effects
In long-term studies on rats and mice, no tramadol-attributed carcinogenic changes were
detected. Histopathologic evaluations showed increased risk of hepatic adenoma in the males
and non dose-related pulmonary adenoma in females. No specific mutations or chromosomal
impairments were detected in rats, mice, or hamsters due to tramadol use. In skin and eye
tests, tramadol had weak corrosive effects on the white rabbits’ eyes but no irritating changes
on their skin [2]. Oral administration of tramadol was reported to have no carcinogenic effects
on the mice and rats. No mutations or increased risk of gene toxicity were detected in human-
beings, either [17].
Tramadol can cause urinary retention because of opioid agonistic effects that can increase the
tonicity of the bladder sphincter [68]. Also, it was shown to have hazardous effects on the
growth, survival, and reproduction system of Daphnia Magna with the most effects on the
latter. Long-term exposures decreased expression of the vtg gene which is an important
biomarker in the reproduction of the oviparous animals [64,95].
In a study by Matthiesen et al, low dose of tramadol had no effect on the fertility, giving birth,
and lactation of the rats and had no teratogenic effects on the fetus [17]. These results are
however in contrast to the results withdrawn by Bornas who mentioned that laboratory studies
had confirmed the teratogenic effects of tramadol on the animals. Tramadol and M1 metabolite
can cross the placenta easily because of their low molecular weights [55].
12. Biochemical findings of tramadol
Bleeding time (BT), clotting time (CT), prothrombin time, partial thromboplastin time, and
body temperature were not affected by tramadol [17]. But, leukocytosis has been reported [44].
Tramadol overdose may result in increased creatine phosphokinase (CPK) which may be seen
with or without seizure and can be accompanied by acute renal failure (Table 2) [13].
Authors Publication
year
Number
of
patients
Sex Co-
administration or
comorbidity
Mortality Findings Dosage or
concentration
Afshari and
Ghooshkhanehee
[14]
2009 Case
report
male _ _ Seizure, confusion,
miosis, dramatic
rise of CPK, LDH,
Cr
4000 mg
Eizadi -Mood
et al. [21]
2011 186 Male=76.6% Addiction history
in 41%, psychotic
disorder in 30.4%,
cardiac disease in
1.1% CNS depression in
57%, bradypnea in
18%, tachycardia in
Mean dosage of
2006±7466 mg
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Authors Publication
year
Number
of
patients
Sex Co-
administration or
comorbidity
Mortality Findings Dosage or
concentration
15%, renal disease
and epilepsy in few
patients
25%, hypertension
in 6%
Talaie
et al. [43]
2009 132 Male=73.5% _ _ Seizure in 46.2% 100-4000 mg
Hassanian-
Moghaddam et al.
[45]
2012 525 Male=70.1% History of
addiction In 16.4%
2.68% Seizure in 46.1%
Apnea in 3.6%
Mean dose of
1358.4±1071.8 mg
Nasif et al. [142] 2010 Case
report
female _ _ Headache,
dizziness, nausea,
drowsiness, visual
hallucinations
500 mg
Khan et al. [143] 2010 Case
report
male _ _ Rhabdomyolysis,
ARF
1000 mg
El-Hussuna et al.
[144]
2010 Case
report
female _ _ Loss of
consciousness,
hypothermia,
tachycardia, atrial
fibrillation in ECG,
hyperamylasemia
3750 mg
Ahmadi et al. [145] 2012 1023 Male=78.5% 26.6% with history
of addiction
21.6% with
coingested drugs
(specially
benzodiazepines)
0.97% Seizure in 41.8% of
patients
Most of patients
less than 5000
mg
Pothiawala et al.
[146]
2011 Case
report
female _ _ Sinus tachycardia Cr=4 mg/L
Dose=700 mg
Taromsari et al.
[147]
2012 306 Male=83% Not mentioned 0.003% Seizure in 20.3%,
agitation in 25.2%
prolonged PT in
18.3%, increased
ALT in 5.6%,
hypotension in
10.5%, Mydriasis in
8.2%, apnea in 2.3%
Mean dose
746±453mg
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Authors Publication
year
Number
of
patients
Sex Co-
administration or
comorbidity
Mortality Findings Dosage or
concentration
Elkalioubie et al.
[148]
2011 Case
report
female _ _ Hypoglycemia
hypothermia, renal
and liver failure,
cardiac arrest,
coagulopathy
4500 mg
Table 2. Studies on patients with tramadol poisoning
13. Serotonin syndrome
Serotonin syndrome (SS) is a potentially fatal syndrome due to increased synthesis, decreased
metabolism, increased release, and reuptake inhibition of serotonin or direct agonism at the
serotonin receptors [5,53]. This syndrome is often due to complex interactions between the
consumed medications. Three key clinical features of this syndrome include:
1. Neuromuscular hyperactivity (tremor, clonus, myoclonus, hyper-reflexia, stiffness,
impaired coordination).
2. Autonomic hyperactivity (profuse sweating, fever, tachycardia, tachypnea, chills, nausea,
diarrhea, vomiting).
3. Mental status changes (agitation, confusion, restlessness, hypomania and/or visual or
auditory hallucinations).
The exact rate of SS is unclear but is generally not expected to occur in more than 5% of the
hospitalized patients [5,44,53,96-98]. The (+) enantiomer of tramadol inhibits re-absorption of
serotonin [99]. Usually, SS happens after tramadol overdose or its concurrent use with other
medications especially antidepressants; however, it may happen even after a single therapeutic
dose of tramadol [5,98,100].
Patients who consume mono amine oxidase (MAO) inhibitors are at the risk of development
of SS [66,101]. SS has been reported after concurrent use of tramadol with serotonin reuptake
inhibitors (SSRIs), venlafaxine, atypical antipsychotics, fluoxetine, sertraline, paroxetine,
citalopram, fluvoxamine, moclobemide, clomipramine, mirtazapine, and tricyclic antidepres‐
sants [5,7,53,97,102].
In patients who develop lethargy, hypotension, hypoxia, agitation, tachycardia, hypertension,
confusion, hyperthermia, or hyper-reflexia, diagnosis of SS should be borne in mind
[7,101,103]. Treatment is conservative and includes cessation of the culpable medication as
well as administration of the antiserotonergics (ciproheptadine, metisergide, propranolol, and
chlorpromazine). Clinical manifestations recover within 24 hours except in those who have
consumed medications with longer half-lives [5,53,97]. Up to 42% of the patients may need
Toxicology Studies - Cells, Drugs and Environment110
ICU admission [48,53]. Pretreatment with chlordiazepoxide may prevent tramadol-induced
SS [48].
14. Drug interactions
Opioids metabolized by CYP450 (including tramadol) may induce many drug-drug interac‐
tions [104]. In an Australian study, unwanted drug interactions were evaluated in 46859
patients who consumed antidepressants. In 8.1% of the patients who had experienced such
complications, the most common consumed medication was tramadol (3.6%). As previously
clarified, tramadol is similar to venlafaxine in structure and is believed to have antidepressant
effects. Venlafaxine can even cause false positive results for tramadol in urine tests [5]. Co-
administration of tramadol and antidepressants especially TCAs, SSRIs, venlafaxine, bupro‐
pion, and phenothiazines should be performed cautiously because of the increased risk of
seizure [6,25,72]. Hallucinations and SS have been reported after co-administration of tramadol
and SSRIs [87]. Concurrent administration of tramadol and NSAIDs can result in gastrointes‐
tinal hemorrhages due to severe platelet inhibition [105]. Fatal toxicities have been reported
after tramadol-TCA overdoses [106]. It has been shown that tramadol-related mortality is more
common after co-ingestion of benzodiazepines [8,26]. Co-administration of tramadol and CNS
depressants, TCAs, and MAO inhibitors are therefore contraindicated [23]. Tramadol can also
interact with antitumor medications. For instance, tramadol decreases the efficacy of cisplatin
by affecting gap junctions [107]. In a case report, combination of paroxetine, dosulepin, and
tramadol caused hallucination which improved after cessation of the medications [108].
15. Tramadol-related mortalities
Fatalities have been reported after tramadol overdose or its co-ingestion with other medica‐
tions. In most cases, death occurred after ingestion of high doses within 24 hours post-ingestion
with really high blood levels [70]. However, death due to tramadol overdose is rare and
consists up to 1% of the hospitalized cases [1,10,44,88]. Blood levels of tramadol have been
between 0.03 to 134 mg/L in different fatal cases [26,32,109,110].
The most common mechanisms of death after tramadol overdose are cardio-respiratory
depression, resistant shock, asystole, and liver failure [111]. Apnea may increase the risk of
tramadol intoxication-related deaths [45]. Fatal toxicity of tramadol has been reported after
co-administration of other medications including propranolol, trazodone, ethanol, and
especially CNS depressants including benzodiazepines, barbiturates, and serotonergic drugs
[88]. M1/M2 (ODT/NDT) metabolite ratio of higher than one in biologic liquids and organs
represents more sudden deaths while M1/M2 < 1 shows that death will occur at later stages
after the tramadol use [32,112]. In fatal cases of tramadol, femoral blood samples are the best
since they have the least redistribution changes after death [113]. Tramadol may remain
undetected in muscle samples after death due to its overdose [114].
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16. Miscellaneous side effects
Mannocchi and assistants reported a case of death due to tramadol and propofol due to
advanced severe dyspnea [115]. A report showed nine deaths due to consumption of krypton
(a plant material containing ODT and mitragynine) in whom the concentration of ODT was
between 0.4 to 4.3 µg/g [116]. Another study reported death due o tramadol because of
respiratory depression accompanying GABA A and GABA B1 alpha1 over-expression in the
ambiguus nucleus and medulla oblongata solitary. (Table 3) [117].
Author Publication
year
Number of
patients
Cause of
ingestion
Cause of death Co-administration
or comorbidity
Dosage or
concentration(C)
Barbera et
al. [32]
2013 Case
report
Suicide Respiratory
depression and
cardiac arrest
Carbamazepine C= 61.83 mg/l
De Decker
et al. [88]
2007 Case
report
Intentional
overdose
Asystole and
multiple organ
failure
Munchausen’s
syndrome,
benzodiazepine
C=8 mg/L
Solarino et
al. [149]
2009 Case
report
Suicide Cardiorespiratory
failure
Nicotine,
diphenhydramine
C= 6.6 mg/L
Ripple et al.
[150]
2000 Case
report
Prescribing
multiple
drugs
Seizure activity Alcohol,
venlafaxine,
trazodone,
quetiapine, lithium,
acetaminophen
C= 0.7 mg/L
Gheshlaghi
et al. [151]
2009 Case
report
Suicide Cardiopulmonary
arrest
_ Dose=1000 mg
Häkkinen et
al. [152]
2012 117 Accidental in
54.8%
Suicide in
31.3%
Unclear
13.9%
Not mentioned Other opioids
detected in 18.8%
Benzodiazepines in
85.5% and alcohol in
14.5%
Median concentration of
5.3 mg/L
Randall and
Crane et al.
[153]
2014 127 Suicide in
38%
Accidental in
27%
Unknown in
35%
Mostly multi organ
or liver failure and
aspiration
pneumonia
Other drug/
medicine in 49%,
alcohol in 36%
C= 1.85-88.8 mg/L
Table 3. Studies on deaths related to tramadol poisoning
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17. Toxicity in children
Accidental ingestion of tramadol is well tolerated by children [50,71,111]. Side effects of
tramadol seem to be more common but milder in children. Vomiting is especially common in
them [118]. Riedel and Stockhausen reported that tramadol could cross the blood brain barrier
(BBB) in children and suppress the brain [119]. Rectal administration of tramadol resulted in
severe CNS depression in a 5-week-old infant which was explained to be due to the decreased
kinetic elimination and increased permeability of the BBB [51]. Mazor et al. reported two cases
of tramadol toxicity with abnormal neurological findings (both seizures and seizure-like
activities) in children [9]. Seizure has been reported after accidental ingestion of 4 mg/kg of
tramadol in children [23].
Short-term use of tramadol in lactating mother is not dangerous [120] and the risk of neonatal
dependency is low.
Tramadol can cause SS without the effect of any other medication while in the adults the risk
is increased if a SSRI is also taken [40]. In an 8-month-old infant with SS, the cause of hospital
presentation was epistaxis. Sinus tachycardia, hyperthermia, hypertension, agitation, drows‐
iness, and hyper-reflexia of the lower extremities occurred within the first 24 hours after
ingestion of 200 mg of tramadol. Neurologic and cardiovascular effects recovered in two days.
The infant was discharged after five days in good condition [121].
18. Treatment
Treatment should focus on conservative approaches including maintenance of airway,
breathing, and circulation, oxygen therapy, fluid resuscitation, and diazepam administration
to control agitation and seizure [6,14,36]. Patients should be monitored for increased CPK and
possible acute renal failure that may happen within the next two days [6,14]. Hemodialysis
should be considered in cases with acute renal failure and severe creatinine increase [14]. They
may need intubation and ICU admission. Gastrointestinal decontamination should be
performed in the patients who have referred within the first two hours post-ingestion and have
no contraindications [8,49,50].
In severe toxicities due to ingestion of large amounts of sustained-release drug, multiple dose
activated charcoal should be considered if no contraindication exists [6,122]. In cases with
resistant shock or asystole, extracorporeal methods may be needed [6,35]. Treatment of liver
failure is conservative, as well, and urgent liver transplantation is not feasible in many cases
[18]. Intubation/ventilation and administration of naloxone are the treatments for tramadol-
induced apnea [45]. In severe cases who have not even seized, experimental therapy with
diazepam can be performed which can be of help in mild undiagnosed SS [6,44]. Treatment of
SS in also conservative and includes withdrawal of the culpable drug and external cooling. Up
to 42% of the patients may need ICU and most of them recover within 12-24 hours [70].
In a clinical study on 122 patients, naloxone administration could induce seizure in tramadol-
intoxicated patients [75]. Therefore, naloxone should not routinely be administered to treat
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decreased level of consciousness in tramadol toxicity unless respiratory depression has
developed [21,45]. Seizures due to tramadol do not respond to naloxone but improve with
administration of benzodiazepines. Naloxone can be considered for treatment of post-seizure
complaints [123].
Shadnia et al suggested that because of the low risk of multiple seizures in tramadol toxicity,
anticonvulsant treatment should not be routinely given even in those with initial seizures [52].
Stoops et al evaluated naltrexone and showed that it could reverse the opioid-induced effects
such as miosis; but, increased the serotonergic and adrenergic effects such as mydriasis [56].
Intravenous lipid emulsion (ILE) can reduce mortality due to acute toxicity of tramadol in
rabbits, but increasing the ILE dose may cause reverse effects. In a study on 30 rabbis, ILE
reduced tramadol-induced tachycardia when administered within 30 minutes of poisoning
and showed positive effects on normalizing mean arterial pressure and diastolic blood
pressure but it did not have major effect on systolic blood pressure. Intralipid also prevented
tramadol-related seizures in low doses and reduced the frequency of increased CPK with
higher doses [124].
19. Dependency and withdrawal
Although tramadol has less side effects, addicting capacity, and respiratory depression power
in comparison with other opioids, many cases of dependency, abuse, intentional overdose, or
poisoning have been reported following its use [20,27,48,56,70,113,125,126]. Tramadol with‐
drawal lasts longer compared with other opioids [111]. Where ultrarapid metabolizers are high
in number, people are expected to have a higher risk of dependency to tramadol [127].
Tramadol is as potent as heroin to cause euphoria [2,55,112]. Withdrawal occurs after rapid
abrupt discontinuation of tramadol with clinical manifestations including abdominal cramps,
anxiety, skeletal pain, depression, diarrhea, goose flesh, insomnia, lacrimation, nausea,
restlessness, rhinorrhea, and sweating. The manifestations may sometimes be atypical and
include hallucination, paranoia, panic attack, confusion, and atypical sensational experiences
such as paresthesia, itching, tingling, delusion, depersonalization, derealization, and tinnitus
[22,55].
Tramadol dependency happens faster in those who abuse it with other analgesics or ethanol
[55]. Clinical therapeutic doses of tramadol may affect psychomotor and physiologic capacities
of the patients who recreationally abuse it [128].
Tramadol abuse in pregnancy may cause preterm labor and withdrawal manifestations in the
newborn baby depending on the age of pregnancy, time elapsed since the beginning of
tramadol use, dose of tramadol, CYP450 D2 polymorphism, development of the liver conju‐
gation, and renal function of both mother and baby. Attempts have been performed to treat
this syndrome in neonates using clonidine alone or in combination with the thin opioid
tinctures, chloral hydrate, benzodiazepines, and methadone [55]. In a study on patients with
chronic non-cancer pain, it was shown that the frequency of abuse and dependency on
tramadol and NSAIDs were the same and significantly less than hydrocodone [129].
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20. Conclusion
Weak opioids such as tramadol can be used in the treatment of reumatologic pains after
development of complications following use of NSAIDs or if they are unable to alleviate the
patients’ pain [130]. It is less dangerous to the organs in comparison with selective and
nonselective NSAIDs and very powerful in the treatment of chronic pains [131]. Tramadol can
also be used in moderate to severe toothaches alone or in combination with acetaminophen or
codeine [132,133]. In opioid-addicted patients, tramadol can be used for the treatment of
withdrawal pain [68]. Tramadol in combination with paracetamol has a fair efficacy, immunity,
and acceptance rate by the patients without development of dependency syndrome
[131,134,135].
Complications can be decreased by adding tramadol to the controlled medications [136].
Monitoring of the liver function especially when the maximum daily doses are given is
mandatory. Also, because of drug-drug interactions and differences in the individual metab‐
olism and the chance of dependency, tramadol administration should be controlled by the
treating physician. If the patient is an opioid-addict, tramadol should not be administered
unless absolutely indicated [137,138].
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